Photodynamic E¤ects in Perifocal, Oedematous Brain Tissue

Background. Photodynamic therapy (PDT) has been under discussion as additional treatment option for malignant gliomas. However, damage not only to tumour tissue but also to normal brain has been demonstrated. The mechanisms of this unwanted side e¤ect have not yet been clearly identified. Spreading of photosensitiser with oedema after disruption of the blood-brain-barrier and potential sensitisation of normal tissue has been found previously. The present study investigates the timeand dose-dependency of normal tissue damage to photodynamic therapy using Photofrin II9 after disruption of the blood-brain-barrier. Methods. Male wistar rats anaesthetised with chloral hydrate were subjected to focal, cerebral cold lesions. Simultaneously, Photofrin II9 (PFII) was injected (2,5 or 5 mg/kg b.w.). Laser irradiation (630 nm) was performed after 4 h, 12 h and 24 h with varying light doses. Control groups were subjected to focal cold lesion alone, cold lesion with laser irradiation, PFII followed by laser irradiation, or laser irradiation alone (n 1⁄4 6 all groups). 24 h later, brains were removed for assessment of necrosis in coronal sections. Findings. Light dose had a significant impact on the extent of necrosis. Compared to control animals (lesion only: 0.84G 0.2 mm; lesion and irradiation alone: 0.7G 0.3 mm), the area of necrosis was increased to 2.8G 0.5 (50 J/cm), 3.5G 1,1 (100 J/cm) and 4.3G 0.7 mm (200 J/cm, 5 mg/kg b.w.; p < 0:01). This e¤ect was time-dependent. Maximal necrosis (6.3G 1,6 mm) was observed when brains were irradiated 12 h after PFII injection, with less necrosis occurring at 24 h (2.8G 0.4 mm, p < 0:01). Reducing sensitiser dose to 2.5 mg/kg b.w. resulted in a reduction of necrosis (2.09G 0.2 mm, p < 0:05Þ. Interpretations. Damage to oedematous tissue after photodynamic therapy using i.v. PFII and laser light at 630 nm depends on laser dose, sensitiser dose and the time point of laser irradiation. The time point of PDT should be considered to prevent unwanted tissue reactions. In the clinical setting however, defined damage to peritumoural tissue may be advantageous. This should be achievable by optimised timing and dosage of photodynamic therapy.

[1]  L. O. Svaasand,et al.  OPTICAL PENETRATION IN HUMAN INTRACRANIAL TUMORS , 1985, Photochemistry and photobiology.

[2]  Satish Krishnamurthy,et al.  Optimal light dose for interstitial photodynamic therapy in treatment for malignant brain tumors , 2000 .

[3]  Andrew H. Kaye,et al.  Photodynamic Therapy of Cerebral Tumors , 1991 .

[4]  A. Kaye.  Photoradiation therapy of brain tumours. , 1989, Ciba Foundation symposium.

[5]  M Chopp,et al.  Sensitivity of 9L gliosarcomas to photodynamic therapy. , 1996, Radiation research.

[6]  A. Kaye,et al.  Selective tumor kill of cerebral glioma by photodynamic therapy using a boronated porphyrin photosensitizer. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[7]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.

[8]  K. Maier-Hauff,et al.  Release of glutamate and of free fatty acids in vasogenic brain edema. , 1989, Journal of neurosurgery.

[9]  A H Kaye,et al.  Phase I and pharmacokinetic study of photodynamic therapy for high-grade gliomas using a novel boronated porphyrin. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  B. Henderson,et al.  SITES OF PHOTODAMAGE in vivo and in vitro BY A CATIONIC PORPHYRIN , 1995, Photochemistry and photobiology.

[11]  P. Wen,et al.  Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma. , 1998, International journal of radiation oncology, biology, physics.

[12]  C. Tengvar.  Extensive intraneuronal spread of horseradish peroxidase from a focus of vasogenic edema into remote areas of central nervous system , 1986, Acta Neuropathologica.

[13]  K. Sartor,et al.  Early Postoperative Magnetic Resonance Imaging after Resection of Malignant Glioma: Objective Evaluation of Residual Tumor and Its Influence on Regrowth and Prognosis , 1995 .

[14]  D. Kessel.  Components of hematoporphyrin derivatives and their tumor-localizing capacity. , 1982, Cancer research.

[15]  H. Sandler,et al.  Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. , 1991, Journal of neurosurgery.

[16]  W. Kamphorst,et al.  Damage to Tumour and Brain by Interstitial Photodynamic Therapy in the 9L Rat Tumour Model Comparing Intravenous and Intratumoral Administration of the Photosensitiser , 1998, Acta Neurochirurgica.

[17]  M Chopp,et al.  Photoactivated Photofrin II: Astrocytic Swelling Precedes Endothelial Injury in Rat Brain , 1992, Journal of neuropathology and experimental neurology.

[18]  S. K. Powers,et al.  Toxicity of photodynamic therapy with photofrin in the normal rat brain , 1994, Lasers in surgery and medicine.

[19]  P. Gutin,et al.  Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. , 1990, International journal of radiation oncology, biology, physics.

[20]  Walter Stummer,et al.  Kinetics of Photofrin II in perifocal brain edema. , 1993, Neurosurgery.

[21]  A H Kaye,et al.  Selective uptake of hematoporphyrin derivative into human cerebral glioma. , 1990, Neurosurgery.

[22]  B. Wilson,et al.  Photodynamic therapy for recurrent supratentorial gliomas. , 1995, Seminars in surgical oncology.

[23]  B. Wilson,et al.  Light propagation in animal tissues in the wavelength range 375-825 nanometers. , 1984, Progress in clinical and biological research.

[24]  M Chopp,et al.  The Effect of Hypothermia and Hyperthermia on Photodynamic Therapy of Normal Brain: 141 , 1995, Neurosurgery.

[25]  A. D. Hoyes,et al.  Cerebral photosensitisation by haematoporphyrin derivative. Evidence for an endothelial site of action. , 1986, British Journal of Cancer.

[26]  C Plangger,et al.  Photodynamic treatment of malignant brain tumors. , 1990, Wiener klinische Wochenschrift.

[27]  S. Brem,et al.  Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. , 1998, Journal of neurosurgery.

[28]  D. Kondziolka,et al.  Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. , 1999, Neurosurgery.

[29]  H. Wiśniewski,et al.  Dynamics of Cold Injury Edema , 1967 .

[30]  T J Dougherty,et al.  The structure of the active component of hematoporphyrin derivative. , 1984, Progress in clinical and biological research.

[31]  S. Stylli,et al.  Selective tumor uptake of a boronated porphyrin in an animal model of cerebral glioma. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Edwards,et al.  Effect of hematoporphyrin derivative photoradiation therapy on survival in the rat 9L gliosarcoma brain-tumor model. , 1985, Journal of neurosurgery.

[33]  A. Kaye,et al.  Photoradiation therapy causing selective tumor kill in a rat glioma model. , 1987, Neurosurgery.

[34]  L. Lilge,et al.  Photodynamic Therapy of 9L Gliosarcoma with Liposome‐Delivered Photofrin , 1997, Photochemistry and photobiology.

[35]  K. Wallner,et al.  Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. , 1989, International journal of radiation oncology, biology, physics.

[36]  A H Kaye,et al.  Photoradiation therapy and its potential in the management of neurological tumors. , 1988, Journal of neurosurgery.

[37]  H. Pass,et al.  Photodynamic therapy in oncology: mechanisms and clinical use. , 1993, Journal of the National Cancer Institute.

[38]  H. Reulen,et al.  Clearance of edema fluid into cerebrospinal fluid. A mechanism for resolution of vasogenic brain edema. , 1978, Journal of neurosurgery.

[39]  B W Henderson,et al.  Tissue localization of photosensitizers and the mechanism of photodynamic tissue destruction. , 1989, Ciba Foundation symposium.

[40]  J. Moan,et al.  Tumor-localizing and photosensitizing properties of the main components of hematoporphyrin derivative. , 1984, Cancer research.

[41]  B. Fisher,et al.  Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. , 1992, International journal of radiation oncology, biology, physics.

[42]  T. Mang,et al.  Dihematoporphyrin ether clearance in primate bladders. , 1986, The Journal of urology.

[43]  J. Spikes.  The Role of the Anatomy, Physiology and Biochemistry of Tumors in the Selective Retention of Sensitizers and the Mechanisms of Photosensitized Tumor Destruction , 1988 .

[44]  Harry T. Whelan,et al.  Preclinical Evaluation of Benzoporphyrin Derivative Combined with a Light-Emitting Diode Array for Photodynamic Therapy of Brain Tumors , 1999, Pediatric Neurosurgery.

[45]  F. Hochberg,et al.  Regrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fields. , 1988, Neurosurgery.

[46]  B. Wilson,et al.  An update on the penetration depth of 630 nm light in normal and malignant human brain tissue in vivo. , 1986, Physics in medicine and biology.